Wrinkle Clinical Trial
Official title:
Clinical Evaluation to Demonstrate the Safety and Performance of the Candela PicoWay System™
Verified date | March 2023 |
Source | Candela Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is intended to demonstrate the safety and efficacy of the PicoWay™ Laser System for its intended uses: clearance of benign pigmented lesions and improvement in appearance of wrinkles.
Status | Active, not recruiting |
Enrollment | 50 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. At least 18 years of age or older 2. Willingness to provide signed, informed consent to participate in the study 3. Presence of mild or greater benign pigmented lesions, and/or wrinkles assessed as Fitzpatrick Wrinkle and Elastosis Score (FWS) >/= 1. 4. Willingness to adhere to study treatment and follow-up schedule 5. Willingness to adhere to post-treatment care instructions 6. Willingness to allow photographs and/or video of treated areas, and to release their use for scientific/educational and/or promotional/marketing purposes 7. Willing to abstain from any other procedures, medications or topicals in the study treatment areas for the duration of the study which the investigator deems would interfere with the study Exclusion Criteria: 1. Pregnant, planning pregnancy during the study, or breast feeding 2. Tattooed skin in the intended treatment area unless tattoo removal treatment is to be performed. 3. Active sun tan in the intended treatment area 4. History of active Herpes Virus Simplex (HSV) or similar condition in the intended treatment area unless treated with prophylactic medication 5. History of melanoma 6. History of vitiligo in the intended treatment area 7. History of keloid or hypertrophic scar formation 8. History of Melasma in the intended treatment area per Investigator's discretion 9. Use of systemic retinoid therapy (e.g. Accutane) during the past 6 months 10. Severe immunosuppression resulting from medications and/or a medical condition that could impair healing after treatment 11. Open wound or infection in the intended treatment area 12. History of light induced seizure disorders 13. The subject is not suitable, in the opinion of the Investigator, for participation in the study due to inability to adhere to the study requirements, medical, or other reasons that could compromise the study integrity or subject safety 14. Dermatologic and/or cosmetic procedures including use of medications, or topicals in the intended treatment area(s) during a timepoint prior to the study that the investigator deems the subject unsuitable for the study |
Country | Name | City | State |
---|---|---|---|
United States | Candela Institute of Excellence | Marlborough | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Candela Corporation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Evaluation Adverse Events | Incidence, severity, and relatedness of adverse events. Severity is rated on a scale from 0 to 4 where 0 = none and 4 = severe | through study completion, approximately 12 months | |
Primary | Benign Pigmented Lesions (BPLs) and Global Aesthetic Improvement Score (GAIS) | Improvement in Benign Pigmented Lesions (BPLs) from Baseline to 3 Month follow-up (= 12 months maximum) via the Investigator Global Aesthetic Improvement Score (IGAIS) where 5 = "worse," and 1 = "very much improved." | 12 months | |
Primary | Benign Pigmented Lesions (BPLs) and Pigment Improvement Score (PIS) | Improvement in Benign Pigmented Lesions (BPLs) from Baseline to 3 Month follow-up (= 12 months maximum) via the Pigment Improvement Score (PIS) where a score of 0 = "no improvement" and a score of 4 = "Excellent response: Most or all lesions much lighter or gone" | 12 months | |
Primary | Wrinkles and Global Aesthetic Improvement Score (GAIS) 3 month follow up | Improvement in the appearance of wrinkles from Baseline 3 Month follow-up (= 12 months maximum) via the Investigator Global Aesthetic Improvement Score (IGAIS) where 5 = "worse," and 1 = "very much improved." | 12 months | |
Primary | Wrinkles and Fitzpatrick Wrinkle and Elastosis Score 3 month follow up | Improvement in the appearance of wrinkles from Baseline 3 Month follow-up (= 12 months maximum) via the Investigator Fitzpatrick Wrinkle and Elastosis Scale where a score of 1 = "fine wrinkles or mild elastosis" and 9 = "deep wrinkles or severe elastosis". | 12 months | |
Secondary | BPLs and Global Aesthetic Improvement Score (GAIS) 1 month follow up | Improvement in BPLs from Baseline to 1 Month follow-up (= 10 months maximum) via the Investigator Global Aesthetic Improvement Score (IGAIS) where 5 = "worse," and 1 = "very much improved." | 10 months | |
Secondary | BPLs and PIS 3 month follow up | Improvement in BPLs from Baseline to 1 Month follow-up (= 10 months maximum) via the Pigment Improvement Score (PIS) where a score of 0 = "no improvement" and a score of 4 = "Excellent response: Most or all lesions much lighter or gone" | 10 months | |
Secondary | Wrinkles and Fitzpatrick Wrinkle and Elastosis Score 1 month follow up | Improvement in the appearance of wrinkles from Baseline to 1 Month follow-up (= 10 months maximum) via the Investigator Fitzpatrick Wrinkle and Elastosis Scale where a score of 1 = "fine wrinkles or mild elastosis" and 9 = "deep wrinkles or severe elastosis". | 10 months | |
Secondary | Wrinkles and Global Aesthetic Improvement Score (GAIS) 1 month follow up | Improvement in the appearance of wrinkles from Baseline to 1 Month follow-up (= 10 months maximum) via the Investigator Global Aesthetic Improvement Score (IGAIS) where 5 = "worse," and 1 = "very much improved." | 10 months | |
Secondary | Overall Subject Satisfaction 3 month follow up | Overall subject satisfaction with study treatments per treatment indication as measured by Subject Satisfaction Scale and Subject Global Aesthetic Improvement Score (SGAIS). (Baseline to 3 month follow up, approximately 12 months) | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05098912 -
Comparing Polydioxanone Thread Embedding Acupuncture and Manual Acupuncture for Nasolabial Fold Reduction
|
N/A | |
Completed |
NCT05271136 -
A Clinical Study to Evaluate the Efficacy of an Anti-Aging Serum
|
N/A | |
Completed |
NCT05096247 -
Post Market Study To Collect Efficacy Data For The Treatment Of Wrinkles With A Radiofrequency Device
|
N/A | |
Completed |
NCT05097157 -
Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions
|
N/A | |
Completed |
NCT04128046 -
The Effect of Platelet-rich Fibrin Matrix on Skin Rejuvenation
|
N/A | |
Active, not recruiting |
NCT06140628 -
A 28-day Clinical Study on Facial Skin Rejuvenation
|
N/A | |
Not yet recruiting |
NCT05524779 -
BTL-785F Device for Non-invasive Reduction of Wrinkles and Overall Facial Improvement
|
N/A | |
Completed |
NCT05514782 -
A Clinical Study to Evaluate the Long-Term Efficacy and Tolerability of a Daily Anti-Aging Daily Serum
|
N/A | |
Completed |
NCT06123572 -
A Clinical Study to Assess the Safety and Effectiveness of Anti-Ageing and Skin Brightening Gel
|
N/A | |
Completed |
NCT04911374 -
An Open-Label Clinical Study to Evaluate the Efficacy of a Face Cream and Eye Cream
|
N/A | |
Recruiting |
NCT04989361 -
Soluble Hyaluronic Acid Microneedle VS. Non-ablative Fractional Laser on Infraorbital Wrinkles.
|
N/A | |
Recruiting |
NCT04540900 -
A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions
|
Phase 1 | |
Recruiting |
NCT06202274 -
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
|
N/A | |
Recruiting |
NCT06074276 -
The Effects of Almond on Facial Skin Collagen and Wrinkles
|
N/A | |
Completed |
NCT06366503 -
Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With Fractional Ablative CO2 Laser for Facial Rejuvenation
|
N/A | |
Active, not recruiting |
NCT06219278 -
A Retrospective Review Evaluating the Matrix Pro Applicator for Treatment of Wrinkles
|
N/A | |
Active, not recruiting |
NCT06192550 -
Functional Usability and Feasibility Testing of the Profound Matrix™ System
|
N/A | |
Completed |
NCT04650620 -
Study to Evaluate the Performance and Safety of the Medical Device Plenhyage®
|
N/A | |
Completed |
NCT03729700 -
The Effect of Almonds on Facial Aesthetics and Modulation of the Microbiome and Lipidome
|
N/A | |
Completed |
NCT05102617 -
Post Market Usability Evaluation Of The PicoSure Pro Device
|
N/A |